FutureBotanica Success, ALS Advocacy, and Canurta’s Expanding Scientific Presence in June 2024

FutureBotanica: The Botanical Drug Ideas of Tomorrow.

We are pleased to share that FutureBotanica 2024, hosted by Canurta Therapeutics, was a resounding success. Held on June 19 at the Ace Hotel Toronto, the event brought together leading voices in biotechnology and life sciences to discuss critical topics in botanical drug development, technology excellence, and sustainability.

One of this event's most significant aspects was the exchange of insights from world-class researchers, industry leaders, and pioneering entrepreneurs. These dialogues enriched attendees' understanding and fostered an environment conducive to collaboration and innovation.

We extend our gratitude to all the speakers, attendees, and sponsors, Applied Pharmaceutical Innovation (API) and Organic Traditions.

Presentation at Mars Impact Health and Collision Conference

Our CEO, Akeem Gardner, showcased the company at the Mars Impact Health and Collision Conference in Toronto on June 12 and 18, respectively. Both pitches were well received by stakeholders, highlighting Canurta's pioneering role in the industry.

During these events, Akeem presented insights into the development of anti-inflammatory and neuroprotective standardized botanical drugs and detailed Canurta's significant achievements and strategic direction.

Thank you to Mars Impact Health and Brampton Angels for the opportunities.

Bronze Sponsor at the Canadian Society for Pharmaceutical Sciences (CSPS) 2024 Symposium

Canurta Therapeutics was honoured to return as a bronze sponsor at the Canadian Society for Pharmaceutical Sciences (CSPS) 2024 Symposium, held in Edmonton, Alberta, from June 10-14. This key event brought together industry leaders, regulatory partners, and academic experts, fostering an environment for collaboration and knowledge exchange in pharmaceutical sciences.

At the symposium, Canurta Therapeutics was represented by Research Associates Kelly Boddington, Ph.D., and Eric Soubeyrand, Ph.D., who presented our work on the formulation of prenylated hemp polyphenols for improved bioavailability. Highlighting our approaches to enhancing the efficacy of botanical drugs.

Visits Partners at Applied Pharmaceutical Innovation in Edmonton, Alberta

On June 10, Canurta Therapeutics' Research Associates, Kelly Boddington, Ph.D., and Eric Soubeyrand, Ph.D., visited our partners Applied Pharmaceutical Innovation in Edmonton, Alberta. This visit was part of our ongoing efforts to enhance our product offerings and explore delivery methods for our botanical therapeutics.

During their time at Applied Pharmaceutical Innovation, they delved into the advanced techniques involved in the production of transdermal and oral strips.

Canurta Therapeutics Joins the Fight Against ALS at the 2024 ALS Canada Pull to End ALS Event

Canurta Therapeutics is excited to participate once again in the ALS Canada Pull to End ALS, scheduled for October 19 at York University. Our team is gearing up to pull a 42,000-lb truck over 100 metres in a spirited effort to support those affected by Amyotrophic Lateral Sclerosis (ALS). This year, we aim to raise $5,000 to surpass our previous achievements.

We need your help to make this happen. Your generous donations will provide crucial support services for the ALS community and fund groundbreaking research through the ALS Society of Canada Research Program.

Together, we can pull towards a future without ALS. Please support our cause by donating today by clicking “Donate” below, and help us make a significant impact together.

Canurta Therapeutics' CEO Participates in the Ice Bucket Challenge

Canurta Therapeutics is proud to participate in the 10th anniversary of the Ice Bucket Challenge, an initiative that has significantly propelled ALS research forward since its launch a decade ago. The challenge sparked a worldwide movement, and we are excited to be part of its lasting impact.

Our engagement in this meaningful campaign begins with our CEO, Akeem Gardner, who leads by example by taking the first icy plunge.

Let us unite in this powerful campaign to advance research further and provide support for those affected by ALS. Together, we can significantly impact the fight against this disease.

Canurta's June Milestones

Research & Development

Advancing Our Solid Lipid Nanoparticle Formulations: Our Research and Development team has dispatched our solid lipid nanoparticle formulations for testing to determine if we have successfully helped our molecules cross the blood-brain barrier.